FOLD - AMICUS THERAPEUTICS, INC.

14.33
-0.010   -0.070%

Share volume: 5,574,104
Last Updated: 03-04-2026
Pharmaceutical Products/Pharmaceutical Preparations: 3.72%

PREVIOUS CLOSE
CHG
CHG%
$14.34
-0.01
0.00%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
28%
Profitability 0%
Dept financing 42%
Liquidity 75%
Performance 40%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
-0.21%
1 Month
0.35%
3 Months
44.75%
6 Months
79.35%
1 Year
56.61%
2 Year
7.34%
Key data
Stock price
$14.33
P/E Ratio 
0.00
DAY RANGE
$14.33 - $14.36
EPS 
-$0.04
52 WEEK RANGE
$5.51 - $14.38
52 WEEK CHANGE
$58.87
MARKET CAP 
4.394 B
YIELD 
N/A
SHARES OUTSTANDING 
314.001 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
08-07-2025
BETA 
0.27
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$3,698,168
AVERAGE 30 VOLUME 
$5,537,500
Company detail
CEO: Bradley L. Campbell
Region: US
Website: amicusrx.com
Employees: 480
IPO year: 2007
Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing

Amicus Therapeutics, Inc. focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease. It also develops AT-GAA, a novel treatment paradigm for Pompe disease; enzyme replacement therapies for Pompe diseases.

Recent news